Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Royal Caribbean Cruises Ltd — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Royal Caribbean Cruises Ltd trades at $275 (market cap $73.36B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 75.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Royal Caribbean Cruises Ltd pays a 2.19% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| MRVI | RCL | |
|---|---|---|
Market Cap | $977.37M | $73.36B |
Volume | 2,742,564 | 1,222,673 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $348.03 |
52-Week Low | $2.83 | $230.30 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $1.08B | $96.01B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Royal Caribbean (RCL) trades at $281.51, up 0.3% with a bullish technical signal. The company shows strong fundamental momentum with Q1 and Q2 2026 earnings beats, robust profitability (23.5% net margin), and improving cash flow. Recent news highlights a $3 billion Sandals Resorts acquisition expanding into the resort market. Technical indicators show the stock trading near pivot point resistance at $285 with strong support at $276.
RCL presents a compelling growth story with accelerating revenue and earnings, though faces execution risks from the Sandals integration and fuel cost pressures. Analyst consensus remains bullish with a $344 price target representing 22% upside potential. The stock's premium valuation (P/E 17.4) appears justified by strong ROE (45.3%) and consistent earnings outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
